GlassScriptPhysician profile
Sherry L Barrett
NPI 1659532778
$2,190.81
in general payments reported to CMS, 2019-2025
25 companies · $641 in 2025
The $641 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $235 · 2022: $228 · 2023: $428 · 2024: $658 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,681 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,680.86 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $483.61 | 2023-2025 | Caplyta |
| Alkermes, INC. | $264.89 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $258.72 | 2021-2025 | Invega Sustenna, Spravato |
| E.R. Squibb & Sons, L.L.C. | $228.72 | 2022-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $151.08 | 2023-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $96.99 | 2024-2025 | Hetlioz, Fanapt |
| Otsuka America Pharmaceutical, INC. | $88.24 | 2023-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $76.69 | 2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $62.80 | 2023-2025 | Uzedy, Austedo Xr |
| Novo Nordisk INC | $57.01 | 2021-2022 | |
| Esperion Therapeutics, INC. | $50.27 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $47.83 | 2021-2022 | |
| Abbvie INC. | $47.72 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.52 | 2021 | |
| Pfizer INC. | $38.91 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $34.79 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.55 | 2022 | |
| Ferring Pharmaceuticals INC. | $24.27 | 2024 | Menopur |
| Idorsia Pharmaceuticals US INC | $18.55 | 2022 | |
| Daiichi Sankyo INC. | $17.67 | 2021 | |
| Lundbeck LLC | $16.86 | 2025 | Abilify Maintena |
| Ucb, INC. | $16.54 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.81 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.19 | 2021 | |
| Eisai INC. | $11.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Barrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.